

# SCIENTIFIC REPORTS



OPEN

## Structural insights into positive and negative allosteric regulation of a G protein-coupled receptor through protein-lipid interactions


Agustín Bruzzese<sup>1,2</sup>, Carles Gil<sup>3</sup>, James A. R. Dalton<sup>1,2</sup>  & Jesús Giraldo<sup>1,2</sup>

Lipids are becoming known as essential allosteric modulators of G protein-coupled receptor (GPCRs). However, how they exert their effects on GPCR conformation at the atomic level is still unclear. In light of recent experimental data, we have performed several long-timescale molecular dynamics (MD) simulations, totalling 24  $\mu$ s, to rigorously map allosteric modulation and conformational changes in the  $\beta_2$  adrenergic receptor ( $\beta_2$ AR) that occur as a result of interactions with three different phospholipids. In particular, we identify different sequential mechanisms behind receptor activation and deactivation, respectively, mediated by specific lipid interactions with key receptor regions. We show that net negatively charged lipids stabilize an active-like state of  $\beta_2$ AR that is able to dock  $G_s\alpha$  protein. Clustering of anionic lipids around the receptor with local distortion of membrane thickness is also apparent. On the other hand, net-neutral zwitterionic lipids inactivate the receptor, generating either fully inactive or intermediate states, with kinetics depending on lipid headgroup charge distribution and hydrophobicity. These chemical differences alter membrane thickness and density, which differentially destabilize the  $\beta_2$ AR active state through lateral compression effects.

G protein-coupled receptors (GPCRs) are implicated in the regulation of many physiological and pathological processes<sup>1</sup>. For this reason, GPCRs are a major target of current marketed drugs<sup>2</sup>. GPCRs are seven-helix transmembrane domain (7TM) receptors that reside in and signal through the lipid membrane of the cell<sup>1</sup>. From an atomistic perspective, GPCRs are flexible proteins that fluctuate between several conformations that can be broadly grouped into inactive, active and intermediate states, and which can be modulated by ligands<sup>3</sup>. The transitions between different conformations, for instance from active to inactive state, can occur along time scales of nanoseconds to milliseconds<sup>4,5</sup>. However, it is still unclear how exactly ligand binding induces (or selects for) receptor activation and elicits efficient signal transduction<sup>3,4,6,7</sup>. In addition to modulation by ligands, phospholipids have been shown to alter the activity of certain proteins by interacting with transmembrane helices, for example in sarcoplasmic reticulum  $Ca^{2+}$ -ATPase, large-conductance mechanosensitive channel MscL, multidrug transporter LmrP, and rhodopsin<sup>8,9</sup>. These effects have typically been shown to be mediated by H-bond formation (or lack thereof) between the protein and phospholipid headgroups<sup>8</sup>. In addition, interactions with cholesterol have been shown to be important for GPCRs, e.g. influencing ionic-lock formation in A2A adenosine receptor<sup>10</sup> and thermal stability of  $\beta_2$  adrenergic receptor ( $\beta_2$ AR)<sup>11</sup>.

Molecular dynamics (MD) is a suitable computational technique for studying GPCR flexibility in its membrane environment. MD simulations at atomic resolution can give information on specific molecular processes, including interactions of proteins with lipids, receptor-ligand binding, and receptor conformational change<sup>12</sup>. Recent X-ray crystal structures of  $\beta_2$ AR have provided high-resolution insights into two major conformations associated with GPCR function: an inactive inverse agonist-bound state<sup>13</sup> and an active state in complex with an agonist and  $G_s$  protein<sup>14</sup>. These crystal structures constitute a reference point for comparison between active and inactive states (see SI Figs 1 and 2). Moreover, the  $\beta_2$ AR is widely expressed throughout the body and can adopt

<sup>1</sup>Laboratory of Molecular Neuropharmacology and Bioinformatics, Institut de Neurociències and Unitat de Bioestadística, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain. <sup>2</sup>Network Biomedical Research Centre on Mental Health (CIBERSAM), 08193 Bellaterra, Spain. <sup>3</sup>Department of Biochemistry and Molecular Biology, Institut de Neurociències, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain. Correspondence and requests for materials should be addressed to J.A.R.D. (email: [james.dalton@uab.es](mailto:james.dalton@uab.es)) or J.G. (email: [jesus.giraldo@uab.es](mailto:jesus.giraldo@uab.es))



**Figure 1.** Structural comparison of DOPC, DOPE and DOPG unsaturated lipids. DOPC (A) contains two fatty-acid chains of 18 carbons each (R) and its headgroup, which is composed of a positively-charged choline group bound to the phosphate group. DOPE (B) contains identical fatty-acid chains but its headgroup is composed of a positively-charged ethanolamine group bound to the phosphate group. DOPG (C) contains identical fatty-acid chains but its headgroup is composed of a neutral glycerol group bound to the phosphate group.

highly diverse conformations with each of them having particular signalling patterns<sup>15</sup>. As such, this receptor constitutes an ideal paradigmatic system for the structural exploration of its (in)activation, both by theoretical and experimental approaches<sup>4,16–19</sup>. From a structure-function perspective, by comparing the active and inactive crystal structures, some authors have emphasized the importance of the rearrangement of transmembrane (TM) helices 5, 6 and 7 in transmitting the signal through the membrane<sup>3–5,20,21</sup>. Further research in this area may include the mechanisms underlying the transitions and fluctuations of  $\beta$ 2AR amongst its many conformational states.

Several MD simulation studies of  $\beta$ 2AR, initialized from its various crystal structures, have been performed before e.g.<sup>4,5,15,16,18,22–33</sup>. Although precise methodological protocols differ, most of these MD simulations share a common theme. By way of summary, the majority do not include intracellular loop 3 (ICL3) of  $\beta$ 2AR<sup>4,5,16,18,22,26–28,30–33</sup>, which is missing in  $\beta$ 2AR crystal structures<sup>11,13,14,34–41</sup> and therefore requires explicit modelling. When the active receptor state(s) is simulated, co-crystallized molecules such as G<sub>s</sub> protein or nanobody are usually first removed<sup>4,22,29,31,32</sup>. In addition, most simulations of  $\beta$ 2AR are performed within a homogeneous membrane consisting of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipids<sup>4,5,16,18,22–28,30–33</sup>. This is due to the relative abundance of this particular phospholipid in healthy mammalian membranes<sup>42</sup>. Noteworthy, MD simulations of  $\beta$ 2AR carried out from the inactive state crystal structure suggest that within this state exist two conformations that are in equilibrium: an inactive (broken ionic-lock) and a very-inactive (closed ionic-lock)<sup>15</sup>. On the other hand, MD simulations starting from the active crystal structure in a POPC membrane (without bound G protein or nanobody) usually result in the spontaneous deactivation of the receptor, even with an agonist bound<sup>4</sup>. This suggests that the preferred state of  $\beta$ 2AR under normal conditions is the inactive, with TM6 fluctuating between a set of inward orientations (representing very inactive, inactive or intermediate), and only adopting an active state with an outward TM6 when a G protein is bound<sup>3,5,17</sup>. However, these observations may be influenced by the absence of ICL3 (which connects TM5 and TM6) in some of these MD simulations. Indeed, in recent MD studies which did include ICL3, receptor behaviour was found to be altered because of noticeable allosteric effects<sup>23,25</sup>. Likewise, experimental data suggests ICL3 is important for the spontaneous activation of  $\beta$ 2AR<sup>43</sup>. Interestingly, recent data gathered in a  $\beta$ 2AR ligand binding study suggests that protein and membrane interplay improves the interaction between protein and ligand and could be important for drug development<sup>26</sup>.

In a related experimental study using artificial nanodiscs, the phospholipids 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG) and 1,2-dioleoyl-sn-glycero-3-phospho-ethanolamine (DOPE) were shown to be strong allosteric modulators of  $\beta$ 2AR, stabilizing and destabilizing the active receptor state, respectively<sup>44</sup>. Furthermore, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), a close relative of POPC, does not favour either active or inactive states and instead allows the receptor to explore different conformations without particular preference<sup>44</sup>. The differences between these three phospholipids lie in the electrostatic charges of their headgroups as all contain the same unsaturated fatty acid chains (two chains of 18 carbons each). Both DOPC (Fig. 1A) and DOPE (Fig. 1B) contain a positively charged headgroup which, in combination with the negatively charged phosphate group, yields a dipole with net neutral charge. The main difference between them is that DOPC has three methyl groups connected to its headgroup nitrogen atom while DOPE has three hydrogens. This makes the DOPC headgroup more hydrophobic, while the corresponding hydrogens in DOPE are free to make ionic/H-bond interactions with other molecules. Other authors have suggested that DOPE and DOPC have different orientations in the membrane due to different intermolecular interactions between P-N groups<sup>45–47</sup>. Unlike the other two, DOPG (Fig. 1C) has a neutral headgroup with two polar hydroxyls which, in combination with the negatively charged phosphate group, yields a net negatively charged phospholipid.

Lipid characterizations of human tissue show that dioleoyl (DO) fatty acid chains are abundant in membranes<sup>48</sup>. Although DOPG lipids specifically have low biological expression (<2%<sup>44</sup>), it represents over >7% of all  $\beta$ 2AR-bound phospholipids (>16% for PG lipids in general)<sup>44</sup>, which possibly indicates enrichment in the vicinity of  $\beta$ 2AR. As lipid composition can be affected by disease, as shown by membrane changes in the brains of Alzheimer's and Parkinson's patients<sup>49–52</sup>, these effects could have a bearing on the activity of GPCRs

such as  $\beta$ 2AR. Along this line of research, recently published MD simulations of  $\beta$ 2AR inserted in a homogeneous 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) membrane has shown that a single anionic lipid is able to disrupt the receptor ionic lock<sup>16</sup>, a typical feature of the inactive (or very-inactive) receptor state<sup>15,16</sup>. This occurs through formation of a salt-bridge between the lipid phosphate group and residue R<sup>3,50</sup> (Ballesteros-Weinstein numbering<sup>53</sup>) of the ionic-lock<sup>16</sup>. Thus, it suggests a possible mechanism by which net negatively charged phospholipids can potentially interact with positively charged residues located at the intracellular side of  $\beta$ 2AR, thereby possibly contributing to the (de)stabilization of the (in)active receptor state.

Despite these findings, a structural explanation of both positive and negative allosteric regulation by phospholipids on  $\beta$ 2AR activity remains unclear. To this aim, we focus on the allosteric effects of DOPG, DOPE, and DOPC phospholipids on the conformational changes of the active state of  $\beta$ 2AR, including modelled ICL3, in unbiased atomistic long-timescale MD simulations. Specifically, we investigate from a structural point-of-view whether these different phospholipids can allosterically modulate  $\beta$ 2AR in a reproducible fashion, either positively or negatively as suggested in analogous experiments<sup>44</sup>, by acting on specific intracellular residues. From a more general perspective, our results potentially open new insights into how phospholipids might influence GPCR behaviour and signalling at a molecular level. In addition, the present study suggests that the choice of membrane lipid composition in computational MD simulations of GPCRs can significantly affect outcome.

## Materials and Methods

**$\beta$ 2AR modelling.** The crystal structure of the active state of  $\beta$ 2AR (PDB entry: 3SN6)<sup>14</sup> was selected. The G<sub>s</sub> protein complex, nanobody, lysozyme-fusion protein, and co-crystallized agonist were removed from the structure. Mutated residues (T96, T98 and E187) were substituted by native ones (M96, M98 and N187) in order to obtain a *wt* receptor sequence. The crystallographic-missing extracellular loop 2 (ECL2) was completed by homology modelling to the corresponding region of the inactive crystal structure of  $\beta$ 2AR (PDB entry: 2RH1)<sup>13</sup> using MODELLER v9.14<sup>54</sup>. Intracellular loop 3 (ICL3) was confirmed using secondary structure prediction tools, Jpred<sup>55</sup> and PSIPred<sup>56</sup> (residues 238 to 262) and then modelled using MODELLER. The complete receptor was then energy-minimized in the AMBER-14SB force-field<sup>57</sup> with CHIMERA<sup>58</sup>.

**Molecular dynamics (MD) simulations.** Three all-atom MD systems were constructed, consisting of  $\beta$ 2AR in active state (as described above) in three homogeneous membranes: DOPG, DOPE and DOPC (Fig. 1), respectively, using CHARMM-GUI<sup>59</sup>. Each receptor-membrane system was solvated with TIP3P water molecules above and below the membrane, with a concentration of 0.3 M KCl for zero system net charge. On the protein, six residues were protonated according to previously published MD simulation protocols specific for  $\beta$ 2AR, as well as being consistent with protocols used for other homologous Class A GPCRs<sup>4,22,60</sup>: D79<sup>2,50</sup>, E122<sup>3,41</sup>, D130<sup>3,49</sup>, D234<sup>5,73</sup>, E237<sup>5,76</sup> and E268<sup>6,30</sup> (Ballesteros-Weinstein numbering<sup>53</sup> as superscript). MD simulations were performed using the CHARMM36 force field<sup>61</sup> and ACEMD software<sup>62</sup>. Briefly, each receptor-membrane system was equilibrated for 28 ns at 300 K and 1 atmosphere. During the initial 8 ns of equilibration, the protein was harmonically restrained and progressively released over 2 ns steps. During the final 20 ns of equilibration, no restraints were applied. For each receptor-membrane system a production run of 4  $\mu$ s was performed without restraints under the same conditions, with a second replicate simulation executed in each case to verify observations. This constitutes a total production simulation time of 24  $\mu$ s.

**MD simulation analysis.** For each MD simulation trajectory, root mean square deviation (RMSD) measurements of the transmembrane (TM) domain (TM helices 1–7 plus helix 8), as well as TM6 or ICL3 by itself, were made with VMD software<sup>63</sup> v1.9.2 in order to evaluate protein conformational changes and stability of receptor state. The distance between the C $\alpha$  atoms of ionic-lock residues R131<sup>3,50</sup> on TM3 and E268<sup>6,30</sup> on TM6 was used as an indication of proximity between these two helices. RMSD of the “triad core”, named by Huang *et al.*<sup>64</sup>, (all heavy atoms of residues: I121<sup>3,40</sup>, P211<sup>5,50</sup> and F282<sup>6,44</sup>) was used as an indicator of receptor state<sup>4,65</sup>. In order to assess membrane characteristics and protein-membrane interactions: (i) the distance(s) between ionic-lock residue R131<sup>3,50</sup> (terminal nitrogen atoms) and closest lipid phosphate group (centre-of-mass) was measured with PLUMED<sup>66</sup>; (ii) membrane thickness calculated as average distance from lower to upper-leaflet phosphorus atoms, implementing default settings of MEMBPLUGIN<sup>67</sup> within VMD<sup>63</sup> over total simulation time; (iii) membrane density calculated across bilayer Z-axis using default settings of MEMBPLUGIN<sup>67</sup>, analyzing mean mass of fatty acid chains and phosphate groups across whole membrane over total simulation time; (iv) area per lipid calculated by dividing total membrane area by total number of upper leaflet lipids (membrane area defined by its maximum X,Y dimensions minus cross-sectional area of protein in the same plane); (v) number of protein-lipid electrostatic interactions calculated every 4 ns between charged lipid atoms of inner-leaflet and charged protein TM6 atoms (counting all charged atom-atom pairs with distance <4.5 Å) using a custom-made script executed within VMD<sup>63</sup>; (vi) radial distribution function implemented twice with the Radial Pair Distribution plugin<sup>68</sup> within VMD<sup>63</sup>: firstly,  $g(r)$  of whole TM6 with respect to lower-leaflet lipid phosphate groups and secondly,  $g(r)$  of positively charged atoms of four lysine sidechains on intracellular side of TM6 (K263<sup>6,25</sup>, K267<sup>6,29</sup>, K270<sup>6,32</sup>, K273<sup>6,35</sup>, Ballesteros-Weinstein numbering<sup>53</sup> as superscript) and negatively charged oxygen atoms of lower-leaflet lipid phosphate groups. As a further validation of receptor state, the co-crystallized G<sub>s</sub> $\alpha$  protein (PDB entry: 3SN6) was docked to the intracellular side of relevant MD-generated  $\beta$ 2AR structures (as well as re-docked into the original active  $\beta$ 2AR crystal structure, PDB entry: 3SN6, as a control). The Rosetta online server (ROSIE) was used for protein-protein docking<sup>69</sup> with the following protocol: (i) receptor conformation taken from the end of its respective 4  $\mu$ s MD simulation and superimposed over the active crystal structure of  $\beta$ 2AR containing its G<sub>s</sub> $\alpha$  protein (PDB entry: 3SN6)<sup>14</sup> (ii) the original crystallized receptor removed from the complex, (iii) the structure of G<sub>s</sub> $\alpha$  moved 3 Å away from the MD-generated receptor structure so that there are no steric clashes and clear space is apparent between both proteins, (iv) protein-protein docking is initiated. As ICL3 is long and potentially highly


flexible, it was removed prior to protein-protein docking (during step iii) so as not to create steric conflicts with  $G_s\alpha$  during docking (ROSIE is not able to move backbone of loops during docking). However, all other loops and receptor structural elements were maintained. All analytical plots were generated using GNUplot<sup>70</sup> version 4.449.

## Results


$\beta$ 2AR is one of the most studied and frequently crystallized Class A GPCRs. However, the structure of intracellular loop 3 (ICL3) that connects TM5 and TM6 is unknown because it is missing in all  $\beta$ 2AR crystal structures. ICL3 has recently been shown to be potentially important in  $\beta$ 2AR activity<sup>23,25</sup>. On this basis, we *ab initio* modelled ICL3 prior to performing MD simulations. As a result,  $\beta$ 2AR contains 13 positively charged residues located at the intracellular ends of TM5, TM6, and ICL3 (SI Fig. 1), which have been suggested as important for G protein interaction<sup>71</sup>.  $\beta$ 2AR has been crystallized in both active ( $G_s$  protein-bound, PDB entry: 3SN6)<sup>14</sup> and inactive (carazolol-bound, PDB entry: 2RH1)<sup>13</sup> states. Briefly, one of the most remarkable differences between them is the orientation of TM6. In the active state, an outward movement of  $\sim 14$  Å is observed (SI Fig. 2). As a result, the ionic-lock ( $R^{3.50}$  and  $E^{6.30}$ , with Ballesteros-Weinstein numbering<sup>53</sup> as superscript, which indicates relative residue position along each TM helix) reaches a distance of 18.9 Å in the active state but only 11.1 Å in the inactive (SI Fig. 2)<sup>13,14</sup>. Other features of the active state include a shortening of TM7 (below the conserved NPxxY motif<sup>74</sup>) where it connects with H8, and an ordered helical second intracellular loop (ICL2), which is disordered in the inactive state (SI Fig. 2)<sup>13</sup>. Mechanistically, the motion of three residues in the core of  $\beta$ 2AR has been shown to be important in the receptor (de)activation process. These residues constitute the triad core:  $I^{3.40}$ ,  $P^{5.50}$  and  $F^{6.44}$  (Ballesteros-Weinstein numbering<sup>53</sup> as superscript), with its packing rearrangement (SI Fig. 2) involved in the relative motions of TM3, TM5 and TM6, serving as a connector between extracellular and intracellular receptor regions<sup>4,65</sup>. In light of observations of relevant  $\beta$ 2AR crystal structures, proposed ICL3 functionality<sup>23</sup>, and experimental data that shows  $\beta$ 2AR is strongly allosterically modulated by different phospholipids<sup>44</sup>, we have investigated the sum of these effects by employing long-timescale MD simulations of the active state of apo  $\beta$ 2AR (PDB entry: 3SN6)<sup>14</sup> in three different homogenous membranes consisting of lipids: DOPC, DOPE and DOPG, respectively. In order to quantify the respective modulation of receptor state by each lipid, six metrics were utilised: conformational re-arrangement of the triad core, ionic-lock distance changes, RMSD of total protein, ICL3, and TM6, as well as radial distribution  $g(r)$  of TM6 with respect to lipids.

**Lipid DOPC partially inactivates  $\beta$ 2-adrenergic receptor.** In a 4  $\mu$ s MD simulation of  $\beta$ 2AR in a homogenous membrane of DOPC, ICL3 shows high flexibility and transiently adopts different conformations during the first microsecond (SI Fig. 3). During this time, the loop does not interact with the membrane but gradually moves to an inward position, interacting with ICL2 on the intracellular side of the receptor, as well as intermittently with H8 (SI Fig. 3). From 1  $\mu$ s onwards,  $\beta$ 2AR maintains ICL3 in this inward conformation (SI Fig. 3). The conformational changes of ICL3 precede a change in the conformation of TM6, which occurs from 2  $\mu$ s onwards. In an RMSD profile of TM6 with respect to the inactive-state crystal structure of  $\beta$ 2AR (PDB entry: 2RH1), TM6 begins at 7.0 Å but decreases to 3.5–5.5 Å from 2  $\mu$ s onwards, finishing at 4.7 Å (SI Fig. 4). This suggests that the receptor is gradually being deactivated (closer in conformation to the inactive state). However, over 4  $\mu$ s, TM6 does not fully reach the conformation of the inactive crystal structure (PDB id: 2RH1) and ICL2 remains in its helical state (Fig. 2). This is despite the receptor containing certain features of the inactive crystal structure such as helical extension at the intracellular end of TM7 (Fig. 2). Likewise, conformational changes are also observed in the triad core, which maintains an active-like conformation of  $I^{3.40}$ ,  $P^{5.50}$  and  $F^{6.44}$  until 3.5  $\mu$ s (Fig. 3), at which point, the RMSD of  $F^{6.44}$  increases to 4.6 Å, which resembles an inactive-like conformation. Supporting the partial inactivation of  $\beta$ 2AR into an intermediate state, the ionic-lock distance gradually decreases to 11.1 Å over 4  $\mu$ s (SI Fig. 5) and the TM domain reaches an RMSD of 3.4 Å compared to the inactive crystal structure (SI Fig. 6). In general terms, this tallies with the experimental results of Dawaliby *et al.*<sup>44</sup>, which show that DOPC neither favours the active or inactive state of  $\beta$ 2AR, but in effect here weakly destabilises the active<sup>44</sup>. Likewise, these results are supported by the computational results of Dror *et al.*<sup>4</sup> whose long-timescale MD simulations of  $\beta$ 2AR in a POPC membrane also exhibited gradual inactivation. Although POPC is not the same as DOPC (POPC contains fatty-acid chains of 18 and 16 carbons, respectively), they both contain the same lipid headgroup and therefore at a chemical level the inter-lipid, water-lipid and protein-lipid interactions would be expected to be similar, which allows for comparison.

**Lipid DOPE fully deactivates  $\beta$ 2-adrenergic receptor.** In a 4  $\mu$ s MD simulation of  $\beta$ 2AR in a homogenous DOPE membrane, like in DOPC, ICL3 shows high flexibility and adopts different conformations during the first 2  $\mu$ s (SI Fig. 3). During this time, ICL3 does not interact with the membrane but does not reach a stable conformation either. Interestingly, the RMSD profile of TM6 shows faster conformational changes than in DOPC, decreasing from 7.0 Å to 1.9 Å within 1  $\mu$ s, when comparing with the inactive crystal structure (SI Fig. 4). This suggests an almost instant destabilization of the active state and fast receptor deactivation. Indeed, at 1  $\mu$ s, TM6 is observed to be in the full inactive conformation (Fig. 4, SI Fig. 4), which does not occur in the DOPC membrane and indicates that DOPE induces greater conformational change, particularly on TM6. In accordance with this inward movement of TM6, the ionic-lock distance also decreases, reaching 7.6 Å between  $R^{3.50}$  and  $E^{6.30}$  at 1  $\mu$ s (SI Fig. 5). This is less than the distance of the “open” ionic-lock in the inactive crystal structure (PDB id: 2RH1) and is indicative of a “closed” ionic-lock, a common feature of fully inactive GPCR crystal structures<sup>15</sup>. Regarding the triad core, its RMSD profile reveals an initial perturbation of  $P^{5.50}$  and  $F^{6.44}$  in the first 0.5  $\mu$ s and then a rapid packing rearrangement of these residues towards an inactive-like conformation at 1  $\mu$ s (Fig. 5). Nevertheless, during this time, the receptor continues to have some active-like features on its intracellular side, such as helical ICL2 and shortened TM7. These continue until 2  $\mu$ s, at which point they also transition into their inactive configurations (Fig. 4, SI Fig. 6). Like in DOPC, ICL3 adopts an inward orientation after 2  $\mu$ s, interacting with ICL2




**Figure 2.** Partial inactivation of  $\beta_2$ AR in a DOPC membrane. Superposition of the inactive-state crystal structure of  $\beta_2$ AR (PDB id: 2RH1, blue) and an MD-generated conformation achieved after 4  $\mu$ s within a DOPC membrane (green), showing a 90° rotation between (A) and (B) around the membrane plane. At the beginning of the MD simulation,  $\beta_2$ AR starts in its active crystal state (PDB id: 3SN6). Intracellular loops (ICL) 2 and 3, and transmembrane (TM) helices 5, 6 and 7 are labelled. Residues of the NPxxY motif on TM7 are displayed.




**Figure 3.** Partial inactivation of the triad core of  $\beta_2$ AR in a DOPC membrane. (A) RMSD profile of the conformational changes of the triad core: I<sup>3.40</sup> (red), P<sup>5.50</sup> (green) and F<sup>6.44</sup> (blue) over a 4  $\mu$ s MD simulation in a DOPC membrane, compared to the active crystal structure (PDB id: 3SN6). (B) Superposition of the triad core observed at 4  $\mu$ s compared to the active crystal structure triad core (orange, PDB id: 3SN6). Relevant residues are labelled: proline (P), isoleucine (I), phenylalanine (F) on transmembrane (TM) helices 3, 5, 6.

(Fig. 4, SI Fig. 3). However, its exact conformation is a little different as it is even more inward than in DOPC, corresponding with what has been previously described as a “very inactive” conformation<sup>15</sup> and remains mostly stable until the end of the simulation (SI Fig. 3). The receptor finally obtains a full complement of inactive-state features from 2.5  $\mu$ s onwards, including a stable triad core (Fig. 5), closed ionic-lock (SI Fig. 5), inward TM6 (SI Fig. 4), disordered ICL2 and extended TM7 (Fig. 4), each of which is in agreement with the inactive-state crystal structure (PDB entry: 2RH1)<sup>13</sup>. In addition, each of these features is maintained until the end of the simulation. This suggests that DOPE membranes can induce and maintain deactivation of  $\beta_2$ AR. Furthermore, this result has been duplicated in a second MD simulation, revealing the reproducibility of this DOPE-mediated deactivation of  $\beta_2$ AR (SI Figs 4–6). Overall, the TM domain transitions from the active state to fully inactive state, including disordered ICL2 and extended TM7 at the NYxxP motif, with an RMSD of 2.5 Å compared to the inactive crystal




**Figure 4.** Full deactivation of  $\beta_2$ AR in a DOPE membrane. Superposition of the inactive crystal structure of  $\beta_2$ AR (PDB id: 2RH1, light blue) and the conformation of  $\beta_2$ AR (dark blue) achieved after a 4  $\mu$ s MD simulation within a DOPE membrane, showing a 90° rotation between (A) and (B) around the membrane plane (extracellular-side: top, intracellular-side: bottom). Beginning from the active crystal structure (PDB id: 3SN6), the receptor reaches an inactive conformation (dark blue), with an almost identical arrangement with respect to the inactive crystal structure (light blue) of helices TM5, TM6, TM7 (residues of the NPxxY motif are displayed), and disordered intracellular loop 2 (ICL2).



**Figure 5.** Full deactivation of the triad core of  $\beta_2$ AR in a DOPE membrane. (A) RMSD profile of the conformational changes of the triad core: I<sup>3.40</sup> (red), P<sup>5.50</sup> (green) and F<sup>6.44</sup> (blue) over a 4  $\mu$ s MD simulation, compared to the inactive crystal structure of  $\beta_2$ AR (PDB id: 2RH1). In this instance, the MD simulation trajectory, which begins from the active state, is aligned to the inactive crystal structure of  $\beta_2$ AR (PDB id: 2RH1). (B) Superposition of the final triad core conformation achieved after 4  $\mu$ s (dark blue) against the inactive crystal structure of  $\beta_2$ AR (light blue). Relevant residues are labelled: proline (P), isoleucine (I), phenylalanine (F) on transmembrane (TM) helices 3, 5, 6.

structure (SI Fig. 6). These observations are in general agreement with the experimental results of Dawaliby *et al.*<sup>44</sup>, who show that DOPE strongly favours the inactive state of  $\beta_2$ AR and destabilises the active<sup>44</sup>.


**Lipid DOPG stabilizes active-like state of  $\beta_2$ -adrenergic receptor.** In a 4  $\mu$ s MD simulation of  $\beta_2$ AR in a DOPG membrane, there is an initial rapid change in the conformation of ICL3, whose RMSD increases by 15 Å compared to its initial modelled state (in the active crystal structure of  $\beta_2$ AR) within the first 0.1  $\mu$ s (SI Fig. 8A). This is due to ICL3 adopting a more outward orientation (SI Fig. 8B), which begins to see it interacts with the DOPG membrane inner layer (Fig. 6, SI Fig. 7). After 0.3  $\mu$ s, positively charged residues on ICL3 make




**Figure 6.** Stabilization of an active-like state of  $\beta_2$ AR by protein-lipid allosteric interactions. (A) An example of DOPG-ICL3/R250 ionic interaction at 4  $\mu$ s in an MD simulation of  $\beta_2$ AR (light magenta) within a DOPG (light blue) membrane. (B) Intracellular view of  $\beta_2$ AR (light magenta) where ionic-lock residue R<sup>3.50</sup> interacts with a DOPG lipid, which protrudes between TM6 and TM7. (C) Protein-lipid interactions over time between R<sup>3.50</sup> and lipid phosphate groups in two MD simulations of  $\beta_2$ AR embedded in a DOPG membrane (DOPG #1 and DOPG #2, respectively).

close interactions with the neutral headgroups and negatively charged phosphate groups of DOPG lipids (for example, Fig. 6A and SI Fig. 7). These protein-lipid interactions are primarily mediated by R250, and to a lesser extent R253 and H256 (SI Fig. 7). This set of ICL3-DOPG interactions is observed throughout the entirety of 4  $\mu$ s, exclusively maintaining ICL3 in an outward orientation (with an RMSD of 15–20 Å, SI Fig. 8A). In addition to the influences of ICL3, TM6 appears to be stabilized in its outward conformation by residues located near its N-terminus, such as H269<sup>6.31</sup>, K270<sup>6.32</sup> and K273<sup>6.35</sup> (Ballesteros-Weinstein numbering<sup>53</sup> as superscript, SI Fig. 7), which are observed to interact with phosphate groups of DOPG lipids, presumably providing an outward pull on the helix. Over 4  $\mu$ s of the simulation, the RMSD of TM6 is 2.0–5.0 Å (compared to the active crystal structure, SI Fig. 9), finishing at 4.3 Å, which is similar to its starting conformation, although slightly more outward (Fig. 7). This may be a consequence of the numerous interactions between ICL3 and TM6 with the membrane, as well as no bound agonist. However, during 1–2  $\mu$ s, TM6 adopts an almost identical conformation to the active crystal structure with an RMSD of 2.0–3.4 Å (SI Fig. 9), which shows this conformation is also relatively stable. As a result of TM6 and ICL3 maintaining outward orientations, the ionic-lock remains open with a distance of 15–21 Å (SI Fig. 5). This is in agreement with the active-state crystal structure of  $\beta_2$ AR<sup>14</sup>. Interestingly, in a previous study, the intrusion of a POPG lipid (a chemically close relative of DOPG, containing an identical lipid headgroup) was observed to occur between TM6 and TM7 of  $\beta_2$ AR in its active state<sup>16</sup>. This POPG lipid was specifically observed to interact with R<sup>3.50</sup> on TM3 (an ionic-lock residue) via a protein-lipid salt-bridge<sup>16</sup>. We can confirm that in addition to the ionic interactions we observe between DOPG lipids and residues on ICL3/TM6, we also observe this extra interaction between R<sup>3.50</sup> and a DOPG lipid in our MD simulations. Specifically, this interaction is formed between R<sup>3.50</sup> and the headgroup/phosphate group of a single DOPG lipid bound between TM6 and TM7 at the intracellular side of  $\beta_2$ AR (Fig. 6), and appears to assist in maintaining TM6 in an outward orientation. Furthermore, this interaction forms very quickly (within the first few hundred nanoseconds of the simulation) and remains mostly stable over 4  $\mu$ s, albeit with some fluctuations (Fig. 6). It is also only observed here in a DOPG membrane. Regarding the triad core of  $\beta_2$ AR in DOPG, residues I<sup>3.40</sup>, P<sup>5.50</sup>, and F<sup>6.44</sup> maintain their same rotameric states as observed in the active crystal structure, exhibiting RMSDs of 1.5, 1.0, and 2.4 Å, respectively (Fig. 8).

As a consequence of the previously mentioned protein-lipid interactions and subsequent stabilization of the triad core in an active-like state, the TM domain is observed to remain in an active-like state over 4  $\mu$ s, including



**Figure 7.** Stabilization of an active-like state of  $\beta_2$ AR in a DOPG membrane. Comparison of the active-state crystal structure (PDB id: 3SN6) of  $\beta_2$ AR (orange) and a receptor conformation (light magenta) achieved after 4  $\mu$ s of an MD simulation within a DOPG membrane, showing 90° rotation between (A) and (B) around the membrane plane (extracellular-side: top, intracellular-side: bottom). Residues of the NPxxY motif on TM7 are displayed. Due to electrostatic interactions between ICL3/TM6 and the membrane, an active-like state of  $\beta_2$ AR is stabilized.




**Figure 8.** Stabilization of the triad core in an active-like state of  $\beta_2$ AR in DOPG. (A) RMSD profile of the conformational changes of the triad core: I<sup>3.40</sup> (red), P<sup>5.50</sup> (green) and F<sup>6.44</sup> (blue) over a 4  $\mu$ s MD simulation, compared to the active crystal structure of  $\beta_2$ AR (PDB id: 3SN6). (B) Superposition of the final MD-generated triad core conformation (light magenta) compared to the active crystal structure (PDB id: 3SN6, orange).

helical ICL2 and shortened TM7 at the NYxxP motif (Fig. 7). This is supported by the overall RMSD of the receptor remaining at 2.0–3.4 Å compared to the initial active crystal structure and finishing at 2.3 Å (SI Fig. 10). Taken together, these results indicate that DOPG lipids are able to stabilize an active-like state of  $\beta_2$ AR, even without a bound G protein or bound agonist. These observations are in general agreement with the experimental results of Dawaliby *et al.*<sup>44</sup>, who show that DOPG strongly favours the active state of  $\beta_2$ AR compared to DOPE and DOPC lipids. Intriguingly, our results may also offer an explanation of basal activity in  $\beta_2$ AR<sup>72</sup>, especially if the lipid environment is chemically similar to that of DOPG.

In order to validate that the DOPG-stabilized receptor conformation was indeed active at a functional level, we re-docked the co-crystallized G<sub>s</sub> $\alpha$  protein (PDB entry: 3SN6) back into the active crystal structure (as a control) and into the MD-generated conformation of  $\beta_2$ AR obtained after 4  $\mu$ s in a DOPG membrane. In both cases, G<sub>s</sub> $\alpha$  is able to adopt an almost identical interaction with the receptor as originally observed in the crystal structure complex without any steric clashes with intracellular loops 1 or 2 (SI Fig. 11). The re-docking of the active crystal structure of  $\beta_2$ AR with G<sub>s</sub> $\alpha$  generates an I<sub>sc</sub> score of −8.0 (ROSIE Interface score from 0 to −10; more





**Figure 9.** Membrane physical characteristics and effect on  $\beta_2$ AR conformation. Membrane thickness measurements from 4  $\mu$ s MD simulations of  $\beta_2$ AR in (A) DOPG, (B) DOPC and (C) DOPE, respectively. (D) Average membrane density measurements from same MD simulations. (E) Radial distribution  $g(r)$  of TM6 with respect to lower leaflet lipids from MD simulations of  $\beta_2$ AR in three different membranes.

negative is better with  $-5$  a threshold for respectable interaction) while the resulting conformation of  $\beta_2$ AR in DOPG with  $G_s\alpha$  has an  $I_{sc}$  of  $-7.5$ . This suggests a similar mode of interaction between  $G_s\alpha$  and  $\beta_2$ AR embedded in a DOPG membrane as observed in the original active crystal structure. As an additional comparison, we also attempted to dock  $G_s\alpha$  into  $\beta_2$ AR conformations generated at the end of respective MD simulations in DOPC and DOPE membranes. In the case of DOPC, a partial interaction between  $G_s\alpha$  and  $\beta_2$ AR was possible resulting in an  $I_{sc}$  of  $-5.8$ , although  $G_s\alpha$  is positioned at a different angle to the active crystal structure and not fully inserted into the receptor. In the case of DOPE, docking is poor with an  $I_{sc}$  of  $-4.7$  and  $G_s\alpha$  is unable to insert into the receptor, making only superficial contacts (SI Fig. 11).

**Membrane characteristics and lipid headgroups facilitate allosteric modulation of  $\beta_2$ AR.** In an effort to explain the different effects that DOPC, DOPE and DOPG membranes have on  $\beta_2$ AR conformational change, we sought to quantify the physical characteristics of each membrane and their specific effects on protein-lipid interaction, specifically with regard to the intracellular conformation of TM6 (key for GPCR activation<sup>3-5,20,21</sup>). Time-averaged membrane thickness measurements reveal that DOPG possesses the greatest degree of intra-membrane variation, with  $>3.0$  Å thickness difference between its periphery and core (i.e. thicker around the protein). This compares with an internal variation of  $<2$  Å for DOPC and  $<1$  Å for DOPE (Fig. 9A–C). This suggests that DOPG lipids preferentially cluster around the protein, whilst less so for DOPC lipids and even less for DOPE whose membrane is nearly uniform. In addition, DOPE constitutes the thickest membrane (some 1.5–2.5 Å thicker than DOPC and 0.5–4.0 Å thicker than DOPG). Likewise, time-averaged membrane density measurements show that the DOPE membrane is most dense, particularly at the level of its headgroups (both upper and lower leaflets, Fig. 9D) whilst DOPG and DOPC membranes are less dense. This translates into an average area per lipid of 61 Å<sup>2</sup> for DOPE, 68 Å<sup>2</sup> for DOPC and 71 Å<sup>2</sup> for DOPG, which are consistent with previously calculated theoretical and experimental measurements<sup>73,74</sup>. As intracellular interactions between phospholipids and the receptor appear to facilitate allosteric modulation in DOPG, we calculated the time-averaged radial distribution  $g(r)$  of TM6 with respect to surrounding lipid phosphate groups in the lower leaflet of each membrane, respectively. This analysis shows that TM6 as a whole in a DOPG membrane has far greater propensity for approaching lipid phosphate groups than in DOPC or DOPE (Fig. 9E). In addition, this propensity is even lower in DOPE than in DOPC, suggesting a different TM6 conformational landscape in each. In order to probe further, we calculated  $g(r)$  a second time, now for just positively charged sidechains located at the intracellular end of TM6 (four lysine residues: K263<sup>6,25</sup>, K267<sup>6,29</sup>, K270<sup>6,32</sup>, K273<sup>6,35</sup>, see SI Fig. 12). This analysis reveals peaks in  $g(r)$  at 4.5–5.0 Å in all three membrane types (DOPG > DOPC > DOPE), which likely reflects electrostatic interactions between positive charges on TM6 and negative charges on lipid phosphate groups. To confirm this hypothesis, we calculated the mean number of electrostatic interactions between charged protein and lipid atoms (distance cut-off  $<4.5$  Å) in the lower leaflet of each membrane (SI Fig. 12). Results show that in DOPG, TM6 makes more protein-lipid electrostatic interactions (2.8 atom-pairs  $\pm$  1.5 SD) than in either DOPC (1.1 atom-pairs  $\pm$  1.0 SD) or


DOPE ( $0.7$  atom-pairs  $\pm 0.8$ SD). Although these differences may not appear marked, over the course of respective MD simulations their effects are cumulative, leading to considerable differences in TM6-lipid attraction. Taken together, the differences in protein-lipid interactions, TM6 conformational landscapes and physical membrane characteristics, a picture of two sets of forces becomes clear. Firstly, attractive protein-lipid interactions, particularly with respect to TM6, maintain the protein in an active-like state in a DOPG membrane, with these same interactions considerably weaker in DOPC and DOPE membranes, respectively. Secondly, different membrane thickness and densities, particularly between DOPC and DOPE, appear to exert different effects on protein conformation. In the case of a DOPE membrane, its greater density and thickness laterally compresses the protein into an inactive state at a faster rate than in DOPC. On the other hand, in a thinner and less dense DOPC membrane, the protein appears to have greater conformational freedom and inactivates slower. At the heart of these differences lie different lipid headgroups. For example, the positively charged headgroup of DOPE lipids create unfavourable interactions with positively charged residues located on TM6, as well as enabling inter-lipid H-bonds between the headgroup of one lipid with the phosphate group of its neighbour (for example, see SI Fig. 13). These charged inter-lipid interactions contribute to the greater density of a DOPE membrane. On the other hand, the more hydrophobic headgroup of DOPC lipids facilitates moderate interaction with TM6, and an absence of inter-lipid H-bonds contributes to lower membrane density.

## Discussion

Taking profit of recent experimental data, which shows phospholipid-mediated allosteric modulation of  $\beta$ 2AR activity<sup>44</sup>, we decided to study the molecular basis behind these effects by simulating  $\beta$ 2AR in three different homogeneous membranes of DOPC, DOPE and DOPG using atomistic molecular dynamics. In remarkable agreement with the experimental data<sup>44</sup>, we have been able to identify how DOPC, DOPE and DOPG differentially modulate  $\beta$ 2AR activity. This receptor modulation consists of either: partial inactivation, full deactivation or stable activation, respectively, and is seemingly governed by the chemistry of protein-interacting lipid headgroups, as no agonists, antagonists, G proteins or nanobodies are included in any of our MD simulations.

DOPG, with its neutral headgroup and negatively charged phosphate group, appears to play a critical role in the stabilization of the active state of  $\beta$ 2AR by making several electrostatic protein-lipid interactions. Firstly, ICL3, through its positively charged residues R250, K253, and R259, interacts with the negatively charged DOPG phosphate groups. Once ICL3 has interacted with the membrane, it is able to maintain a continuous interaction. Secondly, TM6 is able to maintain its outward active conformation through the influences of ICL3, as well as by its own specific attractive interactions between H269<sup>6,31</sup>, K270<sup>6,32</sup> and K273<sup>6,35</sup> with DOPG phosphate groups. In addition, the ionic-lock residue R<sup>3,50</sup> on TM3 is able to interact with the phosphate group of a single DOPG lipid, which is able to protrude between TM6 and TM7 on the intracellular side of the receptor. This appears to assist in the stabilization of the active-like conformation of TM6, although is perhaps less significant than the more direct protein-lipid interactions involving TM6 and ICL3. Consistent with these multiple electrostatic protein-lipid interactions, the radial distribution  $g(r)$  of TM6 with respect to lower-leaflet DOPG lipids is much more pronounced than in other membranes. These results are notable because it has been suggested previously that the active state of GPCRs, including  $\beta$ 2AR, could only be stabilized in MD simulations by bound G proteins or mimetics<sup>3–5,33</sup>. However, our results instead support a pivotal role of lipids in the stable activation of  $\beta$ 2AR, even in the absence of a bound agonist or G protein, ensuring the receptor remains in a conformation that is suitable for G protein binding. Although speculative, this might be the case for other homologous GPCRs too. On the contrary, in a DOPC homogeneous membrane, we observe a slow gradual inactivation of  $\beta$ 2AR, which reaches an intermediate-like state after 4  $\mu$ s. This is an expected result because it is in general agreement with other published MD simulations regarding  $\beta$ 2AR in phosphatidylcholine (PC) lipid membranes, with POPC being the most commonly employed<sup>4,5,16,18,22–28,30–33</sup>. This supports the notion that the active state of  $\beta$ 2AR is inherently unstable and will gradually inactivate without strongly favourable electrostatic protein-lipid interactions (or bound G protein). By analysing the chemical structure and dynamic behaviour observed in DOPC, it is clear why this lipid is unable to make ionic interactions with  $\beta$ 2AR. Although DOPC contains a dipole consisting of  $\text{PO}_4^-$  and  $\text{N}^+$  groups, it has three methyl groups bonded to  $\text{N}^+$ , meaning its headgroup is bulky, hydrophobic and tilted parallel to the surface of the membrane as it seeks to minimize contact with water<sup>45</sup>. As a consequence, its headgroup partially obstructs electrostatic interactions between its phosphate group and positively charged residues on the intracellular side of the receptor. Thus, on average we observe fewer TM6-lipid electrostatic interactions and lower TM6 radial distribution  $g(r)$  in a DOPC membrane compared to DOPG. Finally, the DOPE membrane elicits a similar effect to that of DOPC as it also promotes destabilization of the  $\beta$ 2AR active state. However, the kinetics of this process is notably quicker. In this case,  $\beta$ 2AR undergoes full deactivation to its inactive state within 1.0–2.5  $\mu$ s (depending on simulation analysed). As DOPE does not contain methyl groups on  $\text{N}^+$ , its headgroup is more hydrophilic than DOPC, therefore not as tilted, and instead orientated towards the water phase<sup>45–47</sup>. The exposed  $\text{N}^+$  of DOPE may also have a repulsive effect on positively charged residues located at the intracellular side of TM5, TM6, and ICL3. In particular, this contributes to accelerated deactivation of  $\beta$ 2AR by restricting TM6-lipid electrostatic interactions. In addition, as the DOPE membrane has higher density and thickness compared to DOPC, receptor conformation is more restricted with lower TM6 radial distribution  $g(r)$ .

An additional feature of  $\beta$ 2AR-lipid interaction involves the distortion or thickening of the membrane in the vicinity of the receptor. This is particularly noticeable in DOPG, where membrane thickness increases up to 3 Å or more within a radius of  $\sim 10$  Å around the protein. Interestingly, this effect is also noticeable in DOPC, although to a lesser extent but seems absent in a DOPE membrane. These observations are similar to membrane distortions observed around rhodopsin, where the active state (Meta II) creates local bilayer thickening, not apparent with the inactive state (Meta I)<sup>75</sup>. This can be explained by an increase in the hydrophobic thickness of rhodopsin observed during its activation process, which should then be matched by lipids that are in close proximity<sup>75,76</sup>. Likewise, a similar effect can be seen with sarcoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase, where conformational change



**Figure 10.** Conformational sampling of  $\beta_2$ AR in apo state within DOPC, DOPE and DOPG membranes over respective 4  $\mu$ s MD simulations. Conformational change (RMSD compared to inactive crystal structure, PDB id: 2RH1) of TM7 motif NPxxY against distance between ionic-lock residues ( $R^{3.50}$  and  $E^{6.30}$ ). Data is extracted from 2 to 4  $\mu$ s of each respective MD simulation.

between E1 and E2 states alters the hydrophobic mismatch between protein and membrane, resulting in local bulging or pinching of the bilayer<sup>77,78</sup>. Being homologous to rhodopsin, it is consistent that the active state of  $\beta_2$ AR creates local thickening of the membrane, such as that observed here in a DOPG membrane, in particular. Also, as the active state of  $\beta_2$ AR is destabilized in a DOPC membrane (or fully deactivated in DOPE), it follows that local thickening is less apparent (or absent). Extrapolating from these observations, it would also appear that it is not so much the greater thickness of a DOPE membrane that enhances  $\beta_2$ AR deactivation, but rather its pattern of lipid headgroup charges and associated higher membrane density.

As has been described previously, the active and inactive crystal structures of  $\beta_2$ AR contain different packing arrangements of their triad core<sup>4,65</sup>. In DOPE membranes, we observe the conformational transition of this triad core from active to inactive. This occurs due to the inward movement and rotation of TM6 towards the core of the receptor. This allows  $F^{6.44}$  to move away from  $P^{5.50}$  and relocate onto the other side of  $I^{3.40}$ . However, in DOPC membranes,  $\beta_2$ AR does not reach the full inactive state within the simulated time period. As a result, the triad core fluctuates between inactive and active conformations, with  $F^{6.44}$  able to adopt both inactive-like and active-like orientations due to an intermediate conformation of TM6, which is neither fully inward nor outward. In addition,  $I^{3.40}$  experiences fluctuations in its rotameric state reflecting both inactive-like and active-like conformations. Finally, in DOPG membranes, the triad core of  $\beta_2$ AR is seen to maintain an active-like state, albeit with some minor fluctuations in  $F^{6.44}$ , which is mainly a consequence of initial fluctuations in TM6 (interactions with the membrane are dynamic). Some of these fluctuations in TM6 may also be enhanced by the lack of a bound agonist, which might otherwise help to further stabilize the active state.

A key factor in our observations of lipid-mediated allosteric modulation of  $\beta_2$ AR is the action of ICL3. This non-crystallized region is often neglected in computational studies<sup>4,5,16,18,22,26–28,30–33</sup> but has been shown to be important by experiments<sup>43</sup>. In our experience, it is critical that this highly flexible loop is included as it provides one of the earliest sources of protein conformational change in our MD simulations, making electrostatic interactions with the DOPG membrane (or indeed not making them in the case of DOPC or DOPE). Although we have not directly tested it, we do not believe the active state of  $\beta_2$ AR would be as readily stabilized in DOPG membranes without ICL3, as interactions between this loop and the membrane are so prominent. On this basis, we conclude that ICL3 should ideally be included in all MD simulations of  $\beta_2$ AR, as well as that of other GPCRs, regardless of membrane composition. Despite these observations, other conformational changes besides ICL3 are also important. In particular, TM6 is highly influential in the conformational selection of  $\beta_2$ AR, and provides a connection between ICL3 and the triad core at the centre of the receptor. In addition, the conformation of TM7, which although not directly connected to the triad core or ICL3, is also important, particularly in defining the state of the intracellular G protein binding-site of  $\beta_2$ AR, which displays differences depending on membrane environment. In particular, the conformation of the NPxxY motif<sup>4</sup> located on TM7 (in terms of RMSD) can be used to precisely define receptor state when combined with ionic-lock distance information between TM3 and TM6 (Fig. 10 and SI Fig. 14). In this schematic, the stabilized active-like state of  $\beta_2$ AR in DOPG is clearly distinguishable from that of  $\beta_2$ AR in DOPC (intermediate) or DOPE (inactive). As a consequence, a  $G_s\alpha$  protein can be docked into the DOPG-modulated receptor conformation, obtaining an almost identical fit to that observed in the  $G_s$  protein-bound crystal structure of  $\beta_2$ AR<sup>14</sup>. Another intriguing aspect of  $\beta_2$ AR (and other GPCRs in general) is its known ability to activate G proteins, albeit at a low level, even without the presence of agonists<sup>72</sup>. This is referred to as basal activity<sup>72</sup>. It is also known that the inactive state of  $\beta_2$ AR resides at a lower energy level than the active state<sup>72</sup>. Therefore, in order for the receptor to access and/or remain in the active state, compensating energetic interactions are needed. Our results suggest that in addition to a bound agonist (which is not explicitly simulated here) anionic lipids may provide this additional energy through interactions with the protein, allowing  $\beta_2$ AR to reach its active state. Indeed, this suggests a role of lipids in the regulation of  $\beta_2$ AR basal activity. Likewise, the role of cationic lipids, especially those with an exposed ammonium group, may be to assist in the deactivation of  $\beta_2$ AR, thereby reducing basal activity.

Although beyond the scope of this study, rather than stabilizing or destabilizing the active state of  $\beta_2$ AR, it is interesting to speculate if the reverse process of activating the inactive state of  $\beta_2$ AR could also be induced by lipids during MD simulations. To our knowledge this has not yet been achieved. However, we believe it could be theoretically possible, although longer simulation times than those performed here may be required. In addition,

a bound agonist may also be required to accelerate the kinetics of the process. It is certainly an interesting prospect, and if obtainable, could confirm the hypothesis that lipids have a stronger effect on GPCRs than previously thought. It may also be possible to directly demonstrate basal GPCR activity, for which MD simulations have not yet been able to satisfactorily model. Intriguingly, it has yet to be determined experimentally whether other GPCRs are sensitive to phospholipids in the same way as  $\beta$ 2AR. From our computational results, we observe that electronegative lipids strongly act on  $\beta$ 2AR to stabilize its active conformation(s), while lipids with positively charged headgroups may act to deactivate it. This may hold true for other homologous GPCRs that possess similar patterns of positively charged residues on TM6 and ICL3. Another interesting question concerns how heterogeneous membranes, which likely reflect mammalian physiology more accurately than homogenous membranes, might affect GPCR behaviour through different blends of phospholipids containing a variety of headgroups and fatty acid chains. This is a complex problem requiring further studies but could reveal how specific cellular environments might differentially regulate GPCR-mediated signalling at the molecular level.

**Associated Content.** *Supporting Information.* Comparison of inactive and active  $\beta$ 2AR crystal structures; RMSD plots of ICL3, TM6, and whole protein in DOPG, DOPE, DOPC membranes; plot of ionic-lock distances in DOPG, DOPE, DOPC membranes; visual of selected protein-lipid interactions in DOPG membrane; visual of G protein dockings, plots of electrostatic TM6-lipid interactions and radial distribution  $g(r)$ .

## References

- Katritch, V., Cherezov, V. & Stevens, R. C. Structure-function of the G protein-coupled receptor superfamily. *Annu Rev Pharmacol Toxicol* **53**, 531–556 (2013).
- Santos, R. *et al.* A comprehensive map of molecular drug targets. *Nat Rev Drug Discov* **16**, 19–34 (2017).
- Latorraca, N. R., Venkatakrishnan, A. J. & Dror, R. O. GPCR Dynamics: Structures in Motion. *Chem Rev* **117**, 139–155 (2017).
- Dror, R. O. *et al.* Activation mechanism of the beta2-adrenergic receptor. *Proc Natl Acad Sci USA* **108**, 18684–18689 (2011).
- Nygaard, R. *et al.* The dynamic process of beta(2)-adrenergic receptor activation. *Cell* **152**, 532–542 (2013).
- Staus, D. P. *et al.* Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. *Nature* **535**, 448–452 (2016).
- Gregorio, G. G. *et al.* Single-molecule analysis of ligand efficacy in  $\beta$ 2AR–G-protein activation. *Nature* **547**, 68–73 (2017).
- Lee, A. G. Biological membranes: the importance of molecular detail. *Trends Biochem Sci* **36**, 493–500 (2011).
- Stansfeld, P. J. & Sansom, M. S. Molecular simulation approaches to membrane proteins. *Structure* **19**, 1562–1572 (2011).
- Lyman, E. *et al.* A role for a specific cholesterol interaction in stabilizing the Apo configuration of the human A(2A) adenosine receptor. *Structure* **17**, 1660–1668 (2009).
- Hanson, M. A. *et al.* A specific cholesterol binding site is established by the 2.8 Å structure of the human beta2-adrenergic receptor. *Structure* **16**, 897–905 (2008).
- Lee, E. H., Hsin, J., Sotomayor, M., Comellas, G. & Schulten, K. Discovery through the computational microscope. *Structure* **17**, 1295–1306 (2009).
- Cherezov, V. *et al.* High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. *Science* **318**, 1258–1265 (2007).
- Rasmussen, S. G. F. *et al.* Crystal structure of the  $\beta$ 2 adrenergic receptor–Gs protein complex. *Nature* **477**, 549–555 (2011).
- Dror, R. O. *et al.* Identification of two distinct inactive conformations of the beta2-adrenergic receptor reconciles structural and biochemical observations. *Proc Natl Acad Sci USA* **106**, 4689–4694 (2009).
- Neale, C., Herce, H. D., Pomes, R. & Garcia, A. E. Can Specific Protein-Lipid Interactions Stabilize an Active State of the Beta 2 Adrenergic Receptor? *Biophys J* **109**, 1652–1662 (2015).
- Manglik, A. *et al.* Brian K. Structural Insights into the Dynamic Process of  $\beta$ 2-Adrenergic Receptor Signaling. *Cell* **162**, 1431 (2015).
- Bai, Q. *et al.* Ligand induced change of beta2 adrenergic receptor from active to inactive conformation and its implication for the closed/open state of the water channel: insight from molecular dynamics simulation, free energy calculation and Markov state model analysis. *Phys Chem Chem Phys* **16**, 15874–15885 (2014).
- Chung, K. Y. *et al.* Conformational changes in the G protein Gs induced by the  $\beta$ 2 adrenergic receptor. *Nature* **477**, 611–615 (2011).
- Bang, I. & Choi, H. J. Structural features of beta2 adrenergic receptor: crystal structures and beyond. *Mol Cells* **38**, 105–111 (2015).
- Dalton, J. A., Lans, I. & Giraldo, J. Quantifying conformational changes in GPCRs: glimpse of a common functional mechanism. *BMC Bioinformatics* **16**, 124 (2015).
- Ranganathan, A., Dror, R. O. & Carlsson, J. Insights into the role of Asp79(2.50) in beta2 adrenergic receptor activation from molecular dynamics simulations. *Biochemistry* **53**, 7283–7296 (2014).
- Ozcan, O., Uyar, A., Doruker, P. & Akten, E. D. Effect of intracellular loop 3 on intrinsic dynamics of human beta2-adrenergic receptor. *BMC Struct Biol* **13**, 29 (2013).
- Bai, Q., Zhang, Y., Ban, Y., Liu, H. & Yao, X. Computational study on the different ligands induced conformation change of beta2 adrenergic receptor–Gs protein complex. *PLoS One* **8**, e68138 (2013).
- Ozgun, C., Doruker, P. & Akten, E. D. Investigation of allosteric coupling in human beta2-adrenergic receptor in the presence of intracellular loop 3. *BMC Struct Biol* **16**, 9 (2016).
- Dickson, C. J. *et al.* Uncoupling the Structure-Activity Relationships of beta2 Adrenergic Receptor Ligands from Membrane Binding. *J Med Chem* **59**, 5780–5789 (2016).
- Plazinska, A., Plazinski, W. & Jozwiak, K. Agonist binding by the beta2-adrenergic receptor: an effect of receptor conformation on ligand association-dissociation characteristics. *Eur Biophys J* **44**, 149–163 (2015).
- Dror, R. O. *et al.* Pathway and mechanism of drug binding to G-protein-coupled receptors. *Proc Natl Acad Sci USA* **108**, 13118–13123 (2011).
- Manna, M. *et al.* Mechanism of allosteric regulation of beta2-adrenergic receptor by cholesterol. *Elife* **5**, e18432 (2016).
- Mahmood, I., Liu, X., Neya, S. & Hoshino, T. Influence of lipid composition on the structural stability of g-protein coupled receptor. *Chem Pharm Bull (Tokyo)* **61**, 426–437 (2013).
- Chan, H. C., Filipek, S. & Yuan, S. The Principles of Ligand Specificity on beta-2-adrenergic receptor. *Sci Rep* **6**, 34736 (2016).
- Tikhonova, I. G., Selvam, B., Ivetac, A., Wereszczynski, J. & McCammon, J. A. Simulations of biased agonists in the beta(2) adrenergic receptor with accelerated molecular dynamics. *Biochemistry* **52**, 5593–5603 (2013).
- Sun, X., Agren, H. & Tu, Y. Microsecond Molecular Dynamics Simulations Provide Insight into the Allosteric Mechanism of the Gs Protein Uncoupling from the beta2 Adrenergic Receptor. *J Phys Chem B* **118**, 14737–14744 (2014).
- Ring, A. M. *et al.* Adrenaline-activated structure of  $\beta$ 2-adrenoceptor stabilized by an engineered nanobody. *Nature* **502**, 575–579 (2013).
- Weichert, D. *et al.* Covalent agonists for studying G protein-coupled receptor activation. *Proc Natl Acad Sci USA* **111**, 10744–10748 (2014).

36. Zou, Y., Weis, W. I. & Kobilka, B. K. N-terminal T4 lysozyme fusion facilitates crystallization of a G protein coupled receptor. *PLoS One* **7**, e46039 (2012).
37. Wacker, D. *et al.* Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. *J Am Chem Soc* **132**, 11443–11445 (2010).
38. Bokoch, M. P. *et al.* Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. *Nature* **463**, 108–112 (2010).
39. Rasmussen, S. G. F. *et al.* Crystal structure of the human  $\beta_2$  adrenergic G-protein-coupled receptor. *Nature* **450**, 383–387 (2007).
40. Rasmussen, S. G. *et al.* Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. *Nature* **469**, 175–180 (2011).
41. Rosenbaum, D. M. *et al.* Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. *Nature* **469**, 236–240 (2011).
42. Ackerman, D. G. & Feigenson, G. W. Lipid bilayers: clusters, domains and phases. *Essays Biochem* **57**, 33–42 (2015).
43. Chakir, K. *et al.* The third intracellular loop and the carboxyl terminus of beta2-adrenergic receptor confer spontaneous activity of the receptor. *Molecular pharmacology* **64**, 1048–1058 (2003).
44. Dawaliby, R. *et al.* Allosteric regulation of G protein-coupled receptor activity by phospholipids. *Nat Chem Biol* **12**, 35–39 (2016).
45. Dill, K. A. & Stigter, D. Lateral interactions among phosphatidylcholine and phosphatidylethanolamine head groups in phospholipid monolayers and bilayers. *Biochemistry* **27**, 3446–3453 (1988).
46. Mingins, J., Stigter, D. & Dill, K. A. Phospholipid interactions in model membrane systems. I. Experiments on monolayers. *Biophys J* **61**, 1603–1615 (1992).
47. Stigter, D., Mingins, J. & Dill, K. A. Phospholipid interactions in model membrane systems. II. Theory. *Biophys J* **61**, 1616–1629 (1992).
48. Stillwell, W. In *An Introduction to Biological Membranes* 57–83 (Elsevier, 2013).
49. Mendis, L. H., Grey, A. C., Faull, R. L. & Curtis, M. A. Hippocampal lipid differences in Alzheimer's disease: a human brain study using matrix-assisted laser desorption/ionization-imaging mass spectrometry. *Brain Behav* **6**, e00517 (2016).
50. Martín, V. *et al.* Lipid Alterations in Lipid Rafts from Alzheimer's Disease *Human Brain Cortex*. Vol. 19 (2010).
51. Fabelo, N. *et al.* Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. *Mol Med* **17**, 1107–1118 (2011).
52. Fabelo, N. *et al.* Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer's disease and facilitates APP/BACE1 interactions. *Neurobiol Aging* **35**, 1801–1812 (2014).
53. Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. *Methods in Neurosciences* **25**, 366–428 (1995).
54. Eswar, N., Eramian, D., Webb, B., Shen, M.-Y. & Sali, A. In *Structural Proteomics: High-Throughput Methods* (eds Bostjan Kobe, Mitchell Guss, & Thomas Huber) 145–159 (Humana Press, 2008).
55. Drozdetskiy, A., Cole, C., Procter, J. & Barton, G. J. JPred4: a protein secondary structure prediction server. *Nucleic Acids Res* **43**, W389–394 (2015).
56. Buchan, D. W., Minneci, F., Nugent, T. C., Bryson, K. & Jones, D. T. Scalable web services for the PSIPRED Protein Analysis Workbench. *Nucleic Acids Res* **41**, W349–357 (2013).
57. Case, D. A. *et al.* The Amber biomolecular simulation programs. *J Comput Chem* **26**, 1668–1688 (2005).
58. Pettersen, E. F. *et al.* UCSF Chimera—a visualization system for exploratory research and analysis. *J Comput Chem* **25**, 1605–1612 (2004).
59. Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM. *J Comput Chem* **29**, 1859–1865 (2008).
60. Lans, I., Dalton, J. A. & Giraldo, J. Selective Protonation of Acidic Residues Triggers Opsin Activation. *J Phys Chem B* **119**, 9510–9519 (2015).
61. Huang, J. & MacKerell, A. D. Jr. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. *J Comput Chem* **34**, 2135–2145 (2013).
62. Harvey, M. J., Giupponi, G. & Fabritiis, G. D. ACEMD: Accelerating Biomolecular Dynamics in the Microsecond Time Scale. *J Chem Theory Comput* **5**, 1632–1639 (2009).
63. Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. *J Mol Graph* **14**(33–38), 27–38 (1996).
64. Huang, W. *et al.* Structural insights into  $\mu$ -opioid receptor activation. *Nature* **524**, 315–321 (2015).
65. Valentin-Hansen, L., Holst, B., Frimurer, T. M. & Schwartz, T. W. PheVI:09 (Phe6.44) as a sliding microswitch in seven-transmembrane (7TM) G protein-coupled receptor activation. *J Biol Chem* **287**, 43516–43526 (2012).
66. Bonomi, M. *et al.* PLUMED: A portable plugin for free-energy calculations with molecular dynamics. *Computer Physics Communications* **180**, 1961–1972 (2009).
67. Guixà-González, R. *et al.* MEMBPLUGIN: studying membrane complexity in VMD. *Bioinformatics* **30**, 1478–1480 (2014).
68. Levine, B. G., Stone, J. E. & Kohlmeier, A. Fast Analysis of Molecular Dynamics Trajectories with Graphics Processing Units-Radial Distribution Function Histogramming. *J Comput Phys* **230**, 3556–3569 (2011).
69. Lyskov, S. *et al.* Serverification of molecular modeling applications: the Rosetta Online Server that Includes Everyone (ROSIE). *PLoS One* **8**, e63906 (2013).
70. Williams, T., Kelley, C. & Others. Gnuplot 4.4: an interactive plotting program. 81–87 (2010).
71. Muramatsu, T. & Suwa, M. Statistical analysis and prediction of functional residues effective for GPCR-G-protein coupling selectivity. *Protein Eng Des Sel* **19**, 277–283 (2006).
72. Lamichhane, R. *et al.* Single-molecule view of basal activity and activation mechanisms of the G protein-coupled receptor beta2AR. *Proc Natl Acad Sci USA* **112**, 14254–14259 (2015).
73. Ding, W., Palaiokostas, M., Wang, W. & Orsi, M. Effects of Lipid Composition on Bilayer Membranes Quantified by All-Atom MolecularDynamics. *The journal of physical chemistry. B* **119**, 15263–15274 (2015).
74. Pan, J. *et al.* Molecular structures of fluid phase phosphatidylglycerol bilayers as determined by small angle neutron and X-ray scattering. *Biochimica et biophysica acta* **1818**, 2135–2148 (2012).
75. Brown, M. F. Modulation of rhodopsin function by properties of the membrane bilayer. *Chemistry and physics of lipids* **73**, 159–180 (1994).
76. Mondal, S., Khelashvili, G., Shan, J., Andersen, O. S. & Weinstein, H. Quantitative modeling of membrane deformations by multihelical membrane proteins: application to G-protein coupled receptors. *Biophysical journal* **101**, 2092–2101 (2011).
77. Lee, A. G. How lipids affect the activities of integral membrane proteins. *Biochimica et biophysica acta* **1666**, 62–87 (2004).
78. Andersen, O. S. & Koeppe, R. E. 2nd Bilayer thickness and membrane protein function: an energetic perspective. *Annual review of biophysics and biomolecular structure* **36**, 107–130 (2007).

## Acknowledgements

This study was supported in part by Ministerio de Economía y Competitividad (ERA-NET NEURON PCIN-2013–018-C03–02 and SAF2014–58396-R).

### Author Contributions

A.B. performed modelling, simulations and analysis. All authors contributed to writing and reviewing of the manuscript. J.G. and J.A.R.D. co-supervised study.

### Additional Information

**Supplementary information** accompanies this paper at <https://doi.org/10.1038/s41598-018-22735-6>.

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018